List of Biotech, Pharmaceutical & Life Sciences companies in Poland - 21

Adamed Pharma is a Polish pharmaceutical and biotechnology company that was established thanks to its own scientific thought and its own patents. Currently, it produces approximately 500 products offered to patients in 78 countries around the world. It has representative offices in Spain, Russia, the Czech Republic, Vietnam, Italy, Kazakhstan, Uzbekistan, Slovakia and Ukraine. It currently employs approximately 2,400 people. The company has been conducting its own innovative research and development activities for over 20 years. It cooperates with leading universities and research institutes in Poland and abroad. The company's intellectual property is protected by over 200 patents in most countries around the world. Adamed also owns a controlling stake in Dat Vi Phu, one of the fastest growing local pharmaceutical companies in Vietnam. This transaction was the largest direct Polish investment in Vietnam so far. In 2019, Adamed acquired a block of shares in the Italian company Ecupharma, operating in the field of neuropsychiatry and urology.

AILIS is a pioneering technology. It combines Dynamic Parametric Imaging, artificial intelligence, and telemedicine to immediately detect symptoms of breast cancer and estimate the risk of developing the illness. Our mission is to provide women with dense breasts with access to efficient and comfortable testing based on imaging that detects early symptoms of breast cancer, and to guarantee them with comprehensive care in terms of monitoring their health. Technologies that change the world are always a result of long and hard work of a team of non-accidental people. At AILIS, everyone has a purpose. We are a team of experts and specialists in a number of fields and we share common values. At AILIS, we share common values and principles that we follow in everyday work. To protect the health of millions of women in an honest, responsible, and respectful way. Never to lose our passion for science. And to develop a technology that is authentic in terms of its mission, as well as a service that will become a synonym for protectiveness.

Bioton S.A. - European Biotech Company producing human insulin: API and finished forms in cartridges and vials. For more than 20 years, we have been providing people with diabetes with efficacious and safe medicines. Bioton S.A. is an unquestionable leader on the Polish market, and in the world’s top eight commercial manufacturers of recombinant human insulin. Bioton S.A. continuously invests in the development of Polish biotechnology. We were the first company in Poland which, in cooperation with one of Polish scientific institutes, managed to commercialize the results of the Biotech Transfer. We apply the most current therapeutic and technological solutions to alleviate diabetes treatment for patients. We strive to build comprehensive solutions for the prevention and treatment of diabetes. Bioton S.A. offers CMO/CDMO and QC services. Our activities are based on QbD in line with cGMP standards. Bioton S.A. supplies also a range of innovative gastroenterological FSMP (Foods for Special Medical Purposes).

At Cellis, we are at the forefront of cell-based oncology therapy, specializing in innovative solutions for the treatment of solid tumors. We have developed a breakthrough platform technology called Macrophage Drug Conjugate (MDC), which leverages the revolutionary TRAIN mechanism. This biologic discovery enables the efficient and highly targeted delivery of active compounds directly into the cytoplasm of cancer cells, leading to cell death and tumor shrinkage. MDC also reshapes the tumor microenvironment, fostering immune resistance to cancer growth. Our intellectual property is protected through PCT patent applications, with additional filings pending. As we prepare for first-in-human clinical trials in Q2 2025, we continue to push the boundaries of cancer treatment through integrated therapeutic and diagnostic solutions.

Cellivia is a biotechnology company specializing in: • cell and tissue bioengineering, biotechnology and biomedicine research - own and commercial projects • development and commercialization of innovative therapies and personalized medicines via exosomes • biological material banking for research purposes • bioengineering and robotics in medicine Our mission is to provide personalized medicines and medical therapies based on exosomes. Cellivia‘s team are high-class specialists, including scientists with the professor title, in the field of dentistry, cellular and molecular biology, biotechnology as well as chemical and material bioengineering. The company cooperates with leading universities and research centers in Europe such as the Poznan Science and Technology Park, the Poznan Medical University, the University Hospital and Masaryk University in Brno, Wielkopolska Center for Advanced Technologies. Cellivia conducts a number of research projects, such as the Oral Biology Project - research on the gum and pulp of human teeth; Animal Biology Project - research on animal material from the mucous membrane; Bioexofold - research on biologically active material for reconstruction and regeneration; Bioactive Abutment - research on functionalized titanium. Research projects are used in implemented therapies. The company also carries out pioneering research on chemical and material bioengineering in cooperation with the Poznan Science and Technology Park. Research includes developing a biologically active coating for use in implantology and prosthetics. We have applied for a patent Our Our innovative solutions are being reviewed by Patent Office Cellivia branches: CelliviaLab - area of research and laboratory activities CelliviaDent - the area of dental activity Cellivia Bank - a bank of stem cells and cell lines run for the needs of applied therapies - during the registration procedure

Our mission is to deliver mRNA technology innovations to revolutionize future therapies and the prevention of many diseases. We invent, develop, manufacture and apply our solutions for the benefit of pharmaceutical partners, and to improve people’s lives. With passion, ExploRNA Therapeutics develops ground-breaking innovations of mRNA as a therapeutic platform, applies those solutions in unique therapeutic programs, and delivers technology, therapeutic platform, and therapies to pharmaceutical partners.

Genomtec is a MedTech company specializing in the development of advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system, which allows for fast and precise molecular analysis outside the laboratory environment without the need to involve qualified laboratory personnel. The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections. The solution uses microfluidic technology and proprietary patented SNAAT® isothermal technology. The Genomtec technology is protected by 11 patents, for example, in Europe, the USA, and Japan, with over 35 patent pending applications on global markets. Genomtec's second project in oncology, "OncoSNAAT," consists of developing technology and a new automated system for mutation detection in the field of clinical oncology. This is based on a lab-on-chip solution and isothermal nucleic acid amplification techniques. The company's registered office is located in Wroclaw, Poland. Genomtec also has a branch in the UK, where part of the international research and engineering team is located. Genomtec combines confidence in molecular diagnostics with radical simplicity and cost reduction. The Genomtec team is a unique combination of experienced individuals from various fields with a common passion for creation. We work with a group of young, ambitious scientists and constructors. Everyday, we rely on our outstanding experienced scientists as well as our experts on commercialization and building and enforcing effective market strategies.

IBSS BIOMED S.A. – an expert in vaccines and probiotics – is a Polish biotechnology company operating continuously since 1945. We make exceptional products, which are the effects of the synergy of our experience and the knowledge of reputable research institutes and modern technologies. For over 65 years, we have enjoyed the trust of patients, physicians and business partners. The basis of IBSS BIOMED S.A.'s activity is the production of: probiotics, vaccines (also those included in the Preventive Immunization Schedule), dietary supplements, allergens, as well as diagnostic preparations, media and indicators. We are known for innovative solutions and inventive ideas, which allow us to maintain the highest quality of the manufactured products and, as a result, satisfy customers' expectations. The company constantly improves its products so that they meet quality and market requirements, and are compliant with the highest standards of modern pharmaceutics by: introducing new manufacturing technologies, research methods, modernising the equipment of our laboratories. The areas of the company's activity: Production (own, contract manufacturing and research) R&D of the company's own products (clinical trials, registration) Sales and marketing Export/import

JJP Biologics is an innovative Polish biotechnology company developing novel biological therapies around established companion diagnostics. Our range of programs are in early stage development and we are actively seeking to cooperate with investors and academics on new or existing projects.

Mabion S.A. is a Polish biopharmaceutical CDMO providing extensive drug development and biomanufacturing services to pharmaceutical and Biotech companies globally. We offer services for clinical and commercial manufacture of recombinant protein therapeutics, including process and analytical development services, GMP manufacture of Drug Substance (from small scale up to 4 x 2.000 liter single-use bioreactor sizes), GMP manufacture of Drug Product in our state-of-the-art filling line and an extensive set of analytics and QC tests. This is supported by a robust quality assurance and regulatory affairs department. In addition to our regular CDMO offering, Mabion also took part in the global fight against the coronavirus pandemic by signing a record contract with Novavax Inc. in October 2021 for the commercial production of the antigen for their COVID-19 vaccine. This partnership has proven to be very successful, leading to several subsequent additional services offered by Mabion, augmenting the main commercial-scale manufacturing contract. We aim to establish ourselves as a key global player in the global contract manufacturing and contract drug development market offering a broad range of high-quality integrated services to the Biotech and pharmaceutical market. Mabion is a public Company, listed on the Warsaw Stock Exchange (WSE: MAB). For more information about the Company, please visit www.mabion.eu

NaturalAntibody develops bioinformatics solutions to facilitate the process of engineering antibody-based therapeutics. The company collects, integrates, and repurposes antibody data points across public and proprietary repositories to learn about antibody structure, function, and diversity. Its solutions support researchers in making the process of designing therapeutic antibodies and drug discovery faster and safer.

Polish medtech startup ONGENO has a therapy developed by Dr. Wojciech Orlowski, M.D., which has been proven in the first phase of the experiment to lead to improved sclerosis patient health, reduced disability, and lack of disease progression in the long term.

Ensuring Your Success through Our Passion for Service Your Trusted Partner in Medical Device Manufacturing In today's challenging healthcare environment, you're looking for a contract manufacturer to help simplify the complexities of supply chain and expedite commercialization. As your trusted partner with a shared commitment to quality, you will feel confident as we come alongside to serve as an extension of your team by delivering world class operational excellence and SIOP planning through over a century of combined expertise in high-precision manufacturing, advanced engineering, and design support. You can count on Paragon Medical as your strategic partner in medical device manufacturing, offering an end-to-end supply chain solution from initial concept and product development, to verification and validation testing, to final production, assembly, and ongoing strategic demand planning. Discover how you can experience a consistently remarkable partnership through Paragon Medical's differentiated and personalized solutions designed to exceed your expectations every time.

PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS). PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.

Proteon Pharmaceuticals S.A. uses precision biology for microbiome modulation to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. PROTEON's products improve the economic efficiency in livestock farming and aquaculture, increasing environmental sustainability with natural products that also enhance animal welfare.

Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based on our own technology platforms for the selection of active molecules – antibodies and aptamers. Pure Biologics also offers commercial partnership options in several areas including early phase biological drug discovery and development, selection and characterisation of antibodies and aptamers, as well as protein production, purification and analysis.

Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in cancer and other serious diseases.

Scope Fluidics group is a hub for medtech startups. Scope Fluidics focuses on global challenges in health and accelerates ideas into products by providing legal, financial, and infrastructural resources, as well as critical know‑how. Scope Fluidics provides Curiosity Diagnostics and Bacteromic with a stimulating environment in which engineers and scientists cooperate with clinical experts to deliver groundbreaking medical products.

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.

We are a research and development company that can earn for itself. Thanks to the skilful combination of an extensive sales department and a qualified research team, we are able to provide the latest technological solutions from all over the world and produce completely new, groundbreaking manufacturing methods. We grow in strength from year to year. We want our inventions to effectively change reality. We solve problems in four main areas of activity: - Energy production We are working on new methods of energy storage, which are a necessity in the time of the global climate crisis, requiring an increase in the percentage of Renawable Energy Sources use. - Bioconvergence We want never to run out of organs for transplantation and ensure that no animals have to die in the name of science. Let's bioprint organs for transplantation and create bionic models for drug testing. - Nanotechnology We focus on activities aimed at increasing the presence of nanotechnological achievements in the everyday life of us all. - New additive technologies We create breakthrough solutions that take 3D printing to a completely new level of technological development. We put successive "layers" enabling scientific achievements on a global scale.

Firma TK Biotech została założona w 2001 r. Jesteśmy wyłącznym przedstawicielem w Polsce ponad 30 światowych producentów wybranych produktów z dziedziny Biologii Molekularnej, Biotechnologii oraz Wspomaganego Rozrodu, których charakteryzuje ciągle dążenie do innowacji. Produkty naszych partnerów przyczyniają się do rozwoju nowoczesnej diagnostyki i leczenia. Naszą pozycję zbudowaliśmy na współpracy i rzetelności. Nasz zespół tworzą specjaliści z dziedziny biologii molekularnej, biotechnologii, biochemii oraz biologii, dzięki czemu jesteśmy w stanie zapewnić naszym klientom profesjonalne konsultacje, wsparcie oraz pomoc w wyborze optymalnych rozwiązań. Każdego roku współorganizujemy oraz bierzemy udział w wielu spotkaniach naukowych z dziedziny Biologii Molekularnej, Biotechnologii oraz Wspomaganego Rozrodu, podczas których promujemy najnowsze osiągnięcia swoich partnerów z zagranicy. Zapewniamy Konsultacje i specjalistyczne wsparcie dla naszych klientów Szkolenia aplikacyjne oraz eksploatacyjne Dostawy aparatury oraz odczynników Instalacje i montaż aparatury Serwis techniczny Nasza misja Chcemy brać udział w rozwoju Biologii Molekularnej i Biotechnologii, prowadzącym do nowych odkryć w badaniach podstawowych oraz diagnostyce, aby w ten sposób działać na rzecz poprawy zdrowia i jakości życia społeczeństwa. Chcemy aktywnie uczestniczyć w rozwoju Klinik Wspomaganego Rozrodu, prowadzącym do wdrożenia najnowszych technologii, aby w ten sposób wspomagać dążenia do osiągania wspólnego sukcesu - spełnienia marzeń o szczęśliwym macierzyństwie.